Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Drug makers Harness Experimental Biologics to Broaden Pipeline in Atopic Dermatitis Drugs Market, New Therapies to Help Market Clock CAGR of ~27% during 2019 - 2027:TMR

- Targeted approach of biologic drugs in atopic dermatitis drugs market toward inflammatory responses to propel valuation of the segment to climb from ~US$ 15.3 billion in 2018 to ~US$ 15.3 billion by 2027

- Retail pharmacies to retain its popularity for end users, non-steroid-based option such as topical PDE4 inhibitor drugs to gain traction

Transparency_Market_Research_Logo

News provided by

Transparency Market Research

Sep 14, 2020, 11:30 ET

Share this article

Share toX

Share this article

Share toX

ALBANY, N.Y., Sept. 14, 2020 /PRNewswire/ -- High prevalence and recurrence rate of moderate-to-severe atopic dermatitis, one of the most common chronic inflammation of the skin, has spurred research, paving the way to new therapies in atopic dermatitis drugs market.

High risk of recurrence in adults has nudged healthcare companies to take part in the development of novel therapies to overcome the side effects associated with traditional immunosuppressant medications. In this regard, experimental biologics are attracting sizable research interest.

The share of the biologic drug segment in the global atopic dermatitis drugs market is expected to rise from ~42% in 2018 to ~77% in 2027.

Overall, the global market is expected to expand at robust CAGR of 27% from 2019 to 2027. In 2018, its revenue was pegged at ~US$ 2.2 Bn.

Request for Analysis of COVID-19 Impact on Atopic Dermatitis Drugs Market – https://www.transparencymarketresearch.com/covid19.php

Key Findings of Atopic Dermatitis Drugs Market Report

  • Retail pharmacies are one of the promising segments in the market based on distribution channel
  • The segment to expand from ~US$ 1.3 Bn in 2018 to ~US$ 15.3 Bn by the end of 2027
  • Of all the drug classes, biologics held the leading market share in 2018
  • PDE4 inhibitors segment is the second-leading segment, and is expected to rise at promising growth rate during 2019 – 2027
  • North America contributed the major share in 2018
  • The aforementioned segment is trailed by Europe market
  • The fastest growth rate during the forecast period is expected to come from Asia Pacific

Explore 145 pages of top-notch research, incisive insights, and detailed country-level projections on Atopic Dermatitis Drugs Market (Drug Class: Corticosteroids, PDE4 Inhibitors, Biologics, Skin Barrier Emollients, CNI Immunosuppressants, Others; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027 at https://www.transparencymarketresearch.com/report-toc/73639

Atopic Dermatitis Drugs Market: Key Driving Factors and Promising Avenues

  • Pressing need for the incidence and prevalence in atopic dermatitis is continuously expanding the pipeline in atopic dermatitis drugs market. Per a recent finding, 20% of children and 10% of adults in industrialized countries suffer from this chronic inflammatory skin disease
  • According to a recent epidemiological data, the prevalence is 15–30% in both cohorts.
  • Demand for novel, targeted therapies are attracting the interest of industry players, owing to the potential in increasing the effectiveness of severe atopic dermatitis treatments.
  • The focus on new treatment pathways through experimental biologics is a prominent example of modern therapies.
  • Increasing understanding of pathogenesis of the diseases has shifted the attention away from traditional immunosuppressant, opening new avenues in the atopic dermatitis drugs market.
  • The prevalence of eczema is spurring developments in PDE4 inhibitors segment
  • A multidimensional approach toward the development of pharmacological therapies is boosting new opportunities in the atopic dermatitis drugs market.
  • Growing preference of biologic drugs is one of the key trends that have set the pace of innovation in drug pipelines.

Request Brochure of Atopic Dermatitis Drugs Market Report - https://www.transparencymarketresearch.com/brochure.php

Atopic Dermatitis Drugs Market: Regional Landscape

Regionally, rapidly increasing approvals and fast-paced commercialization of novel therapeutics are the key factors cementing the revenue potential of North America atopic dermatitis drugs market. The regional market is expected to see rapid penetration, with major share of opportunities to come from the U.S. and Canada.

On the other hand, Asia Pacific is expected to rise at remarkable pace during the forecast period. The growing number of new entrants and rise in research investments by established players in this region are boosting the growth. A large patient population has also kept the region increasing lucrative avenue for various drugs makers in the atopic dermatitis drugs market.

Purchase the Atopic Dermatitis Drugs Market Report - https://www.transparencymarketresearch.com/checkout.php

Atopic Dermatitis Drugs Market: Competitive Landscape

Numerous players in recent years have increased their stakes in biologics to gain a competitive edge. They are trying to get fast approvals by agencies such as the U.S. FDA. Most companies are expanding their understanding of the immune and inflammatory pathways underlying severe atopic dermatitis.

Some of the well-entrenched stakeholders in the atopic dermatitis drugs market are Teva Pharmaceutical Industries Ltd., Bausch Health, Novartis AG, Sanofi, and Pfizer, Inc.

Browse More Press Release - https://www.transparencymarketresearch.com/press-releases.htm

The Atopic Dermatitis Drugs market is segmented based on:

Drug Class

  • Corticosteroids
  • Calcineurin Inhibitors
  • PDE4 Inhibitors
  • Biologics

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • U.K.
    • Rest of Europe
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America

Explore Transparency Market Research's award-winning coverage of the global Healthcare Industry:

Venous Skin Ulcer Treatment Market: According to the report, the global venous skin ulcer treatment market was valued at US$ 2.6 Bn in 2019. It is expected to expand at a CAGR of ~5% during the forecast period from 2020 to 2030, the availability of different skin substitutes and rise in patient awareness and healthcare expenditure are major factors that propel the global market

Cosmetic Lasers Market: According to the report, the global cosmetic laser market was valued at US$ 1,455.1 Mn in 2017. It is anticipated to expand at a CAGR of 13.7% from 2018 to 2026, Expansion in the cosmetic industry and rise in awareness about physical appearance among individuals are likely to drive the market

Medical Aesthetic Devices Market: The global medical aesthetic devices market is likely to be driven by the increased adoption of minimally invasive procedures, awareness toward cosmetic procedures, and rising number of obese people in the world. In addition, technological progress in the medical field is likely to drive the demand for medical aesthetic procedures in the years to come

Browse Our Latest Reports - https://www.transparencymarketresearch.com/latest.htm

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision."

Browse More Upcoming Reports by Transparency Market Research: https://www.transparencymarketresearch.com/upcoming.htm

Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Press Release Source: https://www.transparencymarketresearch.com/pressrelease/atopic-dermatitis-drugs-market.htm
Website: https://www.transparencymarketresearch.com/

SOURCE Transparency Market Research

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.